A Christofides
Overview
Explore the profile of A Christofides including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
168
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Banerji V, Aw A, Robinson S, Doucette S, Christofides A, Sehn L
Curr Oncol
. 2020 Dec;
27(6):e645-e655.
PMID: 33380880
Chronic lymphocytic leukemia (cll) is the most commonly diagnosed adult leukemia in Canada. Biologic heterogeneity of cll between patients results in variable disease trajectories and responses to therapy. Notably, compared...
2.
Foley R, Kaedbey R, Song K, Venner C, White D, Doucette S, et al.
Curr Oncol
. 2020 Nov;
27(5):270-274.
PMID: 33173379
The coronavirus disease 2019 (covid-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 has necessitated changes to the way patients with chronic diseases are managed. Given that...
3.
Dolan S, Christofides A, Doucette S, Shafey M
Curr Oncol
. 2020 Sep;
27(4):e420-e432.
PMID: 32905290
Because of the global coronavirus pandemic, the 2020 annual scientific meeting of the American Society of Clinical Oncology took place virtually, 29-30 May. At the meeting, results from key studies...
4.
Sehn L, Kuruvilla P, Christofides A, Stakiw J
Curr Oncol
. 2020 Jul;
27(3):e332-e335.
PMID: 32669941
The emergence of the covid-19 disease pandemic caused by the 2019 novel coronavirus has required a re-evaluation of treatment practices for clinicians caring for patients with chronic lymphocytic leukemia (cll)....
5.
Banerji V, Anglin P, Christofides A, Doucette S, Laneuville P
Curr Oncol
. 2020 Jun;
27(2):e231-e245.
PMID: 32489274
The 2019 annual meeting of the American Society of Hematology took place 7-10 December in Orlando, Florida. At the meeting, results from key studies in treatment-naïve chronic lymphocytic leukemia (cll)...
6.
Stewart D, Aucoin J, Crosbie T, Forman M, Lye E, Christofides A, et al.
Curr Oncol
. 2020 Jun;
27(2):113-116.
PMID: 32489254
Results of studies comparing subcutaneous (sc) with intravenous (iv) rituximab indicate that the two formulations are comparable in efficacy, but most patients and health care professionals prefer the sc route,...
7.
LeBlanc R, Song K, White D, Christofides A, Doucette S
Curr Oncol
. 2019 Sep;
26(4):e581-e594.
PMID: 31548829
The 2019 annual meetings of the American Society of Clinical Oncology and the European Hematology Association took place, respectively, in Chicago, Illinois, 31 May-4 June, and in Amsterdam, Netherlands, 13-16...
8.
Skrabek P, Assouline S, Christofides A, MacDonald D, Prica A, Sangha R, et al.
Curr Oncol
. 2019 Sep;
26(4):253-265.
PMID: 31548805
Diffuse large B cell lymphoma (dlbcl) is an aggressive non-Hodgkin lymphoma, accounting for approximately 30% of lymphoma cases in Canada. Although most patients will achieve a cure, up to 40%...
9.
Yip S, Christofides A, Banerji S, Downes M, Izevbaye I, Lo B, et al.
Curr Oncol
. 2019 May;
26(2):e241-e254.
PMID: 31043833
Rapid advancements in next-generation sequencing (ngs) technology have created an unprecedented opportunity to decipher the molecular profile of tumours to more effectively prevent, diagnose, and treat cancer. Oncologists now have...
10.
Owen C, Berinstein N, Christofides A, Sehn L
Curr Oncol
. 2019 May;
26(2):e233-e240.
PMID: 31043832
Mantle cell lymphoma (mcl) is a rare subtype of aggressive B-cell non-Hodgkin lymphoma that remains incurable with standard therapy. Patients typically require multiple lines of therapy, and those with relapsed...